Loading...
XSTO
BIOVIC B
Market cap8mUSD
Oct 07, Last price  
0.29SEK
1D
-3.95%
1Q
-23.16%
IPO
-97.72%
Name

Biovica International AB

Chart & performance

D1W1MN
XSTO:BIOVIC B chart
P/E
—
P/S
6.06
EPS
—
Div yield, %
—
Shrs. gr., 5y
50.36%
Rev. gr., 5y
45.15%
Revenues
13m
+55.24%
4,045,026459,0002,432,000632,0002,723,0003,005,0001,671,0002,077,0002,045,0003,384,0007,290,0008,619,00013,380,000
Net income
-70m
L-20.27%
-5,371,659-7,043,000-5,031,000-14,857,000-18,064,000-21,556,000-30,318,000-39,483,000-60,003,000-110,492,000-124,823,000-87,624,000-69,860,000
CFO
-63m
L-26.43%
0922,000-9,385,000-11,090,000-14,882,000-17,966,000-24,780,000-34,409,000-52,126,000-94,640,000-114,575,000-85,367,000-62,806,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Biovica International AB (publ) operates as a biotechnology enterprise, concentrating on the development and market introduction of sophisticated blood-based biomarker tests. These diagnostic solutions aim to enhance the tracking and prediction of cancer treatment efficacy across Sweden and globally, with a significant focus on breast cancer. A key offering is DiviTum, a biomarker assay engineered to measure the activity levels of the enzyme thymidine kinase-1 within blood serum or cell cultures. The company's clientele includes oncology research centers, pharmaceutical corporations, and various collaborative organizations. Established in 2008, Biovica's main office is situated in Uppsala, Sweden.

Related entities

Subsidiaries
Biovica Services AB

Key people

Lars Holmqvist
Chairman of the Board · since 2019
Anders Rylander
Chief Executive Officer, Director
Cecilia Driving
Chief Financial Officer
Christina Andersson
Operations Manager
Mattias Bergqvist
Vice President Marketing and Clinical Development
Gabriel Sack
Business Development Manager
Johanna Faris
Regulatory and Quality Assurance Director
Otti Bengtsson Gref
Research & Development Director · since 2020
Maria Birgitte Holmlund
Director · since 2016
Jarl Ulf Jungnelius
Director
Henrik Osvald
Director · since 2019
Jesper Soderqvist
Director
URL
https://biovica.com/
IPO date
Mar 29, 2017
Employees
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Dag Hammarskjölds väg 54B
Uppsala, C 752 37
SE
Address
Dag Hammarskjolds vag 54B
Uppsala, C 752 37
SE
Previous name
Rönnerbol International AB

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑042025‑042024‑042023‑042022‑042021‑042020‑042019‑042018‑042017‑04
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT